ArticleDermatology and therapy2025

Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

Diamant Thaçi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.